BCYC vs. AVTE, LBPH, YMAB, PHAR, ORIC, SLN, SIGA, ZYME, PRTC, and PRAX
Should you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Aerovate Therapeutics (AVTE), Longboard Pharmaceuticals (LBPH), Y-mAbs Therapeutics (YMAB), Pharming Group (PHAR), ORIC Pharmaceuticals (ORIC), Silence Therapeutics (SLN), SIGA Technologies (SIGA), Zymeworks (ZYME), PureTech Health (PRTC), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical preparations" industry.
Bicycle Therapeutics (NASDAQ:BCYC) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.
Bicycle Therapeutics received 103 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. Likewise, 68.39% of users gave Bicycle Therapeutics an outperform vote while only 64.00% of users gave Aerovate Therapeutics an outperform vote.
Bicycle Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
Aerovate Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -669.72%. Bicycle Therapeutics' return on equity of -57.80% beat Aerovate Therapeutics' return on equity.
86.2% of Bicycle Therapeutics shares are owned by institutional investors. 10.2% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 19.3% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Bicycle Therapeutics presently has a consensus target price of $46.86, suggesting a potential upside of 106.60%. Aerovate Therapeutics has a consensus target price of $49.33, suggesting a potential upside of 112.46%. Given Aerovate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aerovate Therapeutics is more favorable than Bicycle Therapeutics.
In the previous week, Aerovate Therapeutics had 4 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 10 mentions for Aerovate Therapeutics and 6 mentions for Bicycle Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.46 beat Bicycle Therapeutics' score of 0.27 indicating that Aerovate Therapeutics is being referred to more favorably in the news media.
Aerovate Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Aerovate Therapeutics beats Bicycle Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Bicycle Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bicycle Therapeutics Competitors List
Related Companies and Tools
